- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- High Intensity Interval Exercise, Dietary Approaches to Stop Hypertension (DASH) Diet, Exercise + DASH Diet
- Behavioral
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 371
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Adult Subjects, Sickle Cell Disease
- Interventions
- FTX-6058/placebo oral capsule(s), FTX-6058 - Two Dosing Periods, FTX-6058 / Midazolam Syrup
- Drug
- Lead sponsor
- Fulcrum Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Overland Park, Kansas
- Conditions
- Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
- Interventions
- Liraglutide, Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Healthy
- Interventions
- PF-06821497 Treatment A, PF-06821497 Treatment B, PF-06821497 Treatment C, PF-06821497 Treatment D, PF-06821497 Treatment E, PF-06821497 Treatment F
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy Volunteers
- Interventions
- Apremilast Tablet, Apremilast Oral Suspension
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Healthy Volunteer
- Interventions
- Venetoclax
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Grayslake, Illinois • Austin, Texas
- Conditions
- Healthy, Healthy Aging
- Interventions
- Fatty meal to challenge the physiological chronobiome in healthy young and old
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy Adults
- Interventions
- sitravatinib
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Cabotegravir 30 mg
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Coccidioidomycosis
- Interventions
- Placebo, VT-1598
- Other · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Knee Osteoarthritis
- Interventions
- Diet, Exercise
- Other
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- College Station, Texas
- Conditions
- Healthy Volunteers
- Interventions
- TAK-227
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Pediatric Obesity, Insulin Resistance
- Interventions
- High-fat Challenge
- Dietary Supplement
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Healthy
- Interventions
- MK-1403 formulation (FM) 1 + additive, MK-1403 FM2 + additive
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- South Miami, Florida
- Conditions
- type1diabetes, Obesity
- Interventions
- Hyperinsulinemic-euglycemic clamp, High Fat Mixed Meal Tolerance Test
- Biological · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Understanding of Food Nutrient Content
- Interventions
- Front-of-package label
- Behavioral
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 4,052 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Davis, California
- Conditions
- Weight Management
- Interventions
- GS-4571, Placebo, Omeprazole
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 3
- States / cities
- Miami, Florida • San Antonio, Texas • Salt Lake City, Utah
- Conditions
- Healthy Volunteers
- Interventions
- AZD5055 solution for infusion, AZD5055 oral suspension, AZD5055 film-coated tablet, Rabeprazole, Delayed-release tablet
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Prostatic Hyperplasia
- Interventions
- Treatment sequence A, Treatment sequence B, Treatment sequence C
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy Volunteer
- Interventions
- GDC-0310, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Carcinoma, Ductal, Breast, Breast Cancer Female, Breast Neoplasm, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Stage IV Breast Cancer
- Interventions
- G1T48, Palbociclib
- Drug
- Lead sponsor
- G1 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Stanford, California • Chicago, Illinois + 3 more
- Conditions
- Healthy Participants
- Interventions
- Zibotentan/Dapagliflozin FDC
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Healthy Volunteer
- Interventions
- Alectinib, Posaconazole
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Clinical Pharmacology, Healthy Male Volunteer Study
- Interventions
- CC-122
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida